Johnson & Johnson Vision to Acquire TearScience

August 4, 2017: By Jon Swedien

JJV logo x300Johnson & Johnson Vision announced Aug. 4 that it has signed a definitive agreement to acquire TearScience, a Morrisville, North Carolina, company that develops and markets products for meibomian gland dysfunction (MGD), an underlying cause of dry eye disease.

Financial terms were not disclosed.

The deal is expected to close by the end of the year, J&J Vision said. Following the closing, sales will be reported in J&J’s Medical Devices segment, under Vision Care, the company said. J&J Vision’s ophthalmic surgery division is located in Santa Ana, California.

TearScience received FDA clearance in July 2011 for its LipiFlow system, an office-based approach to image meibomian glands and treat MGD. The company sells its products in the US and major markets globally, J&J Vision said.

The TearScience acquisition strengthens J&J Vision’s portfolio, allowing it to provide a critical solution to its optometric and ophthalmic customers who serve dry eye patients, company officials said.


Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022